Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582836 | 1.00 | HCAR2 (0.56) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL691282 | 1.00 | HCAR2 (0.56) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL24962297 | 0.87 | HCAR2 (0.52) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL28096079 | 0.84 | HCAR2 (0.54) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL2545648 | 0.84 | HCAR2 (0.54) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL2799607 | 0.84 | HCAR2 (0.54) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL12798478 | 0.84 | HCAR2 (0.54) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL30640686 | 0.84 | HCAR2 (0.54) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL18561871 | 0.83 | HCAR2 (0.52) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL11800870 | 0.83 | HCAR2 (0.52) | HCAR2MAPTNPSR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113631535-B | Heteroaryl and bisheteroaryl derivatives for the treatment of iron death-related disorders | 协同医药发展有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117813289-A | Pyrazole derivatives, intermediates thereof and process for preparing same | 上海海雁医药科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20230147833-A1 | OPTICALLY PURE OXASPIRO-SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230128062-A1 | AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| WO-2023284775-A1 | PYRAZOLE DERIVATIVE, AND INTERMEDIATE THEREOF AND PREPARATION METHOD THEREFOR | 上海海雁医药科技有限公司 | 2023-01-19 | — | — | WO | disclosed |
| CN-108699098-B | C-glucoside derivative having fused benzene ring or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition comprising same | 第一药品株式会社 | 2022-01-25 | — | — | CN | disclosed |
| WO-2021188762-A1 | BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME | NITTO DENKO CORPORATION (JP) | 2021-09-23 | — | — | WO | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| WO-2001019837-A1 | AN IMPROVED REGIOSPECIFIC SYNTHESIS OF PHOSPHONOUS ACIDS | LUPIN LABORATORIES LIMITED (IN) | 2001-03-22 | — | — | WO | disclosed |
| US-5859268-A | FROM MONOOLEFIN ESTER USING IRON PENTACARBONYL | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0251370-B1 | Cyclohexane-, cyclohexene- and cyclohexadiene, bicyclo[2.2.1]heptane and bicyclo [2.2.1]heptenecarboxylic acid esters, and also perfume compositions and perfumed products which contain one or more of said compounds as perfume component | NAARDEN INTERNATIONAL N.V. (NL) | 1989-10-25 | — | — | EP | disclosed |
| US-4843061-A | ORGANOLEPTIC | NAARDEN INTERNATIONAL N.V. (NL) | 1989-06-27 | — | — | US | disclosed |
| EP-0251370-A1 | Cyclohexane-, cyclohexene- and cyclohexadiene, bicyclo[2.2.1]heptane and bicyclo [2.2.1]heptenecarboxylic acid esters, and also perfume compositions and perfumed products which contain one or more of said compounds as perfume component | NAARDEN INTERNATIONAL N.V. (NL) | 1988-01-07 | — | — | EP | disclosed |
| US-3987176-A | COMPOSITION AND USE OF 3,4-DIHYDROPYRIDONES AS VASODILATORS AND ANTIHYPERTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-10-19 | — | — | US | disclosed |
| US-3981882-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-21 | — | — | US | disclosed |
| US-3951990-A | CORONARY AGENTS, HYPOTENSIVE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3951991-A | CORONARY AGENTS, HYPOTENSIVE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3951992-A | CORONARY, HYPOTENSIVE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147833-A1 | OPTICALLY PURE OXASPIRO-SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | WEE1, CYP51A1, CYP4F11 | HCAR2 1795/4885MAPT 3045/4885NPSR1 1495/4885 |
| US-20230128062-A1 | AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP4A11, CYP51A1, CYP4F11 | HCAR2 362/4885MAPT 4454/4885NPSR1 734/4885 |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | HCAR2 429/4885MAPT 2834/4885NPSR1 394/4885 |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | HCAR2 4340/4885MAPT 2276/4885NPSR1 4337/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | HCAR2 4309/4885MAPT 2314/4885NPSR1 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.